Compare KTF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTF | IMNM |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.2M | 2.5B |
| IPO Year | N/A | 2020 |
| Metric | KTF | IMNM |
|---|---|---|
| Price | $8.46 | $23.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 168.9K | ★ 847.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | $21.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.45 | $8.93 |
| 52 Week High | $9.37 | $30.06 |
| Indicator | KTF | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 17.14 | 39.68 |
| Support Level | N/A | $23.67 |
| Resistance Level | $9.25 | $25.07 |
| Average True Range (ATR) | 0.06 | 1.00 |
| MACD | -0.03 | -0.54 |
| Stochastic Oscillator | 2.31 | 15.53 |
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.